Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Analysts are predicting strong performance driven by the strong demand of Lilly's blockbuster drugs, particularly the diabetes franchise. However, there are also concerns about potential challeng